

ASX Announcement

Medibio Limited – 15 September 2016



Medibio and Monash groundbreaking partnership on innovation for sleep and mental health solution

Sydney, Australia – 15 September 2016: Medibio Limited (MEB or the Company) is pleased to announce that it has established a partnership with the Monash Institute of Cognitive and Clinical Neurosciences (MICCN) to create innovative approaches to improve sleep and mental health outcomes in the general population. By bringing together Monash University's world-leading sleep and circadian expertise and Medibio's mental health diagnostics capabilities, the collaboration will translate cutting-edge science into next-generation mental health solutions.

The Monash Institute of Cognitive and Clinical Sciences (MICCN) is the largest Institute of its type in the Asia Pacific region, uniting over 200 world-class researchers with cutting-edge research infrastructure. The Institute is dedicated to understanding the brain and mind - specifically in key integrated research programs of attention and memory, sleep, and addiction, seeking to directly and actively support the use of this knowledge in the clinic, the workplace, and also through collaborations with industry and the community.

The Medibio-MICCN partnership will involve a broad range of initiatives focused on the further development of Medibio's early detection and monitoring solutions and MICCN's advanced research and treatment approaches for sleep and circadian disorders for the clinical and work setting. This partnership opens opportunities for access to a wealth of data from sleep disorder and other groups of patients through the Monash Sleep Network.

Medibio's contribution to funding the project for the first 12 months is covered by the contingency for unplanned costs already factored into Medibio's budget.

Director of MICCN's Sleep Program, Professor Shantha Rajaratnam, said the partnership brought together Monash's world leading expertise with industry partner Medibio to improve sleep and mental health outcomes for individuals. ***"The partnership leverages Monash Institute of Cognitive Science's high impact research and world leading capability in sleep science and advanced diagnostic and treatment approaches for sleep disorders with the world-class mental health analytics capabilities of Medibio.***

"This collaboration with Medibio is an exciting and significant strategic step for MICCN as we look to translate our research into real-world outcomes through deep and enduring partnerships with industry".

In commenting on the partnership, Kris Knauer, Medibio's CEO said: *"Given the market's shift to value-based health care, MICCN provides extensive insights into sleep related services that provide meaningful clinical outcomes and economic value in the area of mental health."*

Further Information:		Website: www.medibio.com.au
Medibio Shareholder Enquiries to: Kris Knauer CEO and Director Medibio Limited kris.knauer@medibio.com.au T: +61 (0)411 885979	Medibio Media Enquiries to: Peter Taylor NWR Communications peter@nwrcommunications.com.au T: +61 (0)412 036 231	

About Monash University

Monash is the largest university in Australia, and amongst the most highly regarded in the world. Over fifty years we've built a reputation for quality teaching, world-leading research, and an inspiring learning culture. Part of the Group of Eight Universities, and with a presence on four continents, we're ranked in the top one per cent of universities worldwide. But it's the impact we have on those who study and work here that's of most importance to us. Monash students leave with a greater sense of purpose, a global outlook, and the skills and confidence to make positive change – to their own lives, and to the lives of those around them.

About Medibio Limited

Medibio (ASX: MEB), is a medical technology company that has developed an objective test to assist in the diagnosis of depression, chronic stress and other mental health disorders. Based on research conducted over 15 years at the University of Western Australia, this test utilizes patented (and patent pending) circadian heart rate variability and cloud based proprietary algorithms delivering a quantifiable measure to assist in clinical diagnosis. Medibio's depression diagnostic is being validated in clinical studies undertaken by Johns Hopkins University School of Medicine and The University of Ottawa, among others. The clinical trials will support Medibio's application to become the first FDA approved, objective, and evidence based approach to the diagnosis of mental health disorders. Medibio's technology also provides an objective method for the assessment of stress and mental wellbeing that can be translated to the workplace stress/wellbeing market, wearable technology, and App market. Located in Melbourne, VIC, Medibio is listed on the Australian Securities Exchange.